ly3437943 retatrutide (LY3437943): Mechanism of Action and Research Overview Retatrutide (LY3437943) | GIP/GLP-1/GCGR agonist
Description
Store and monitor your testing strips
Individual results vary based on starting weight, dose, diet, and activity level
Cancel before 11:59 p.m
All three retatrutide groups had a greater reduction in apnea-hypopnea Index from baseline to 80 weeks compared with placebo
2024 Jan 5
